Track GT Gain Therapeutics SA — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

GT Gain Therapeutics SA GANX · Stock Open GT Gain Therapeutics SA in new tab

1.04 USD
EPS
-0.50
P/B
4.14
ROE
-268.30
Beta
0.30
Target Price
7.20 USD
Loading chart...
Key Metrics
Earnings dateMarch 25, 2027
EPS-0.50
Book Value0.26
Price to Book4.14
Debt/Equity5.40
% Insiders2.234%
Estimates
Forward P/E-1.57
Forward EPS-0.69
Target Mean Price7.20

DCF valuation

Model fair value for GT Gain Therapeutics SA (GANX)
Result
Sign in to run the valuation for GANX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
5 analysts · consensus Strong buy · mean target 7.20 USD (low 5.00, high 8.00) · as of 11 Nov 2026
Low 5.00
Mean 7.20
High 8.00
Price 1.04
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

GT Gain Therapeutics SA Logo GT Gain Therapeutics SA Analysis (GANX)

United States Health Care Official Website Stock

Is GT Gain Therapeutics SA a good investment? GT Gain Therapeutics SA (GANX) is currently trading at 1.04 USD. Market analysts have a consensus price target of 7.20 USD. This suggests a potential upside from current levels.

Earnings Schedule: GT Gain Therapeutics SA is expected to release its next earnings report on March 25, 2027. The market consensus estimate for Forward EPS is -0.69.

Investor FAQ

Does GT Gain Therapeutics SA pay a dividend?

No, it does not currently pay a dividend.

What asset class is GT Gain Therapeutics SA?

GT Gain Therapeutics SA is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 25, 2027. The company currently has a trailing EPS of -0.50.

Company Profile

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.

Exchange Ticker
NMS (United States) GANX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion